Finally, combined treatment with PI3K inhibitors and ERK2 or bRAF inhibitors showed synergistic effects in vitro and in vivo on patient‐derived glioblastoma mouse model, showing that TRF1 targeting via phosphorylation inhibition could be a promising strategy. The gene discussed is TERF1; the disease is glioblastoma.